Freestone Capital Holdings LLC Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

Freestone Capital Holdings LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 7.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 68,075 shares of the company’s stock after buying an additional 4,454 shares during the period. Freestone Capital Holdings LLC’s holdings in Johnson & Johnson were worth $9,930,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Financial Advantage Inc. purchased a new position in Johnson & Johnson in the third quarter valued at about $28,000. Kessler Investment Group LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at about $29,000. Exchange Traded Concepts LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at about $31,000. Eii Capital Management Inc. purchased a new position in Johnson & Johnson in the third quarter valued at about $39,000. Finally, Permanens Capital L.P. increased its holdings in Johnson & Johnson by 33.3% in the third quarter. Permanens Capital L.P. now owns 400 shares of the company’s stock valued at $52,000 after buying an additional 100 shares in the last quarter. 67.38% of the stock is owned by institutional investors.

In related news, COO Michael E. Sneed sold 58,128 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $149.39, for a total transaction of $8,683,741.92. Following the sale, the chief operating officer now owns 107,511 shares in the company, valued at $16,061,068.29. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Kathryn E. Wengel sold 2,017 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $141.07, for a total transaction of $284,538.19. Following the sale, the executive vice president now owns 51,736 shares in the company, valued at approximately $7,298,397.52. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by company insiders.

Several analysts have recently commented on JNJ shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $168.00 price target on shares of Johnson & Johnson in a research report on Thursday, January 23rd. Credit Suisse Group increased their price target on shares of Johnson & Johnson from $163.00 to $170.00 and gave the company an “outperform” rating in a research report on Monday, January 27th. Barclays upgraded shares of Johnson & Johnson from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $140.00 to $173.00 in a research report on Thursday, December 19th. Raymond James increased their price target on shares of Johnson & Johnson from $147.00 to $161.00 and gave the company an “outperform” rating in a research report on Thursday, January 23rd. Finally, Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $158.00 price target on the stock in a research report on Wednesday, December 18th. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Buy” and a consensus target price of $161.92.

JNJ stock opened at $150.13 on Friday. The company’s 50 day simple moving average is $148.09 and its 200-day simple moving average is $136.84. The firm has a market capitalization of $395.02 billion, a PE ratio of 17.29, a P/E/G ratio of 2.50 and a beta of 0.69. Johnson & Johnson has a 12 month low of $126.10 and a 12 month high of $154.50. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.26 and a quick ratio of 1.00.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $1.88 EPS for the quarter, beating the consensus estimate of $1.87 by $0.01. Johnson & Johnson had a net margin of 22.18% and a return on equity of 39.30%. The business had revenue of $20.75 billion for the quarter, compared to analyst estimates of $20.83 billion. During the same period in the prior year, the business earned $1.97 earnings per share. The company’s quarterly revenue was up 1.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Johnson & Johnson will post 9.03 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 25th will be given a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, February 24th. This represents a $3.80 dividend on an annualized basis and a yield of 2.53%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 43.78%.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Equal Weight Rating

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.